Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Eastell, R; Black, DM; Boonen, S; Adami, S; Felsenberg, D; Lippuner, K; Cummings, SR; Delmas, PD; Palermo, L; Mesenbrink, P; Cauley, JA; HORIZON Pivotal Fracture Trial.
Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
J Clin Endocrinol Metab. 2009; 94(9): 3215-3225. Doi: 10.1210/jc.2008-2765 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Study Group Members Med Uni Graz:: Dobnig Harald
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: CONTEXT: In the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly - Pivotal Fracture Trial (HORIZON-PFT), zoledronic acid (ZOL) 5 mg significantly reduced fracture risk. OBJECTIVE: The aim of the study was to identify factors associated with greater efficacy during ZOL 5 mg treatment. DESIGN, SETTING, AND PATIENTS: We conducted a subgroup analysis (preplanned and post hoc) of a multicenter, double-blind, placebo-controlled, 36-month trial in 7765 women with postmenopausal osteoporosis. Intervention: A single infusion of ZOL 5 mg or placebo was administered at baseline, 12, and 24 months. MAIN OUTCOME MEASURES: Primary endpoints were new vertebral fracture and hip fracture. Secondary endpoints were nonvertebral fracture and change in femoral neck bone mineral density (BMD). Baseline risk factor subgroups were age, BMD T-score and vertebral fracture status, total hip BMD, race, weight, geographical region, smoking, height loss, history of falls, physical activity, prior bisphosphonates, creatinine clearance, body mass index, and concomitant osteoporosis medications. RESULTS: Greater ZOL induced effects on vertebral fracture risk were seen with younger age (treatment-by-subgroup interaction, P = 0.05), normal creatinine clearance (P = 0.04), and body mass index >or= 25 kg/m(2) (P = 0.02). There were no significant treatment-factor interactions for hip or nonvertebral fracture or for change in BMD. CONCLUSIONS: ZOL appeared more effective in preventing vertebral fracture in younger women, overweight/obese women, and women with normal renal function. ZOL had similar effects irrespective of fracture risk factors or femoral neck BMD.
Find related publications in this database (using NLM MeSH Indexing): Aged -; Aged, 80 and over -; Body Mass Index -; Bone Density - drug effects; Bone Density Conservation Agents - therapeutic use; Diphosphonates - therapeutic use; Double-Blind Method -; Female -; Femur Neck - drug effectsFemur Neck - metabolism; Hip Fractures - prevention and control; Humans -; Imidazoles - therapeutic use; Spinal Fractures - prevention and control